3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Breast
2
Conditions
Carcinoma, Non-Small-Cell Lung
78
Lung Neoplasms
44
Carcinoma, Hepatocellular
42
Small Cell Lung Carcinoma
29
Breast Neoplasms
18
Cholangiocarcinoma
17
Urinary Bladder Neoplasms
16
Biliary Tract Neoplasms
15
Liver Neoplasms
13
Neoplasms
12
Neoplasm Metastasis
12
Triple Negative Breast Neoplasms
11
Pancreatic Neoplasms
11
Ovarian Neoplasms
10
Carcinoma
9
Squamous Cell Carcinoma of Head and Neck
8
Endometrial Neoplasms
7
Colorectal Neoplasms
7
Stomach Neoplasms
6
Carcinoma, Transitional Cell
6
Melanoma
5
Gallbladder Neoplasms
5
Esophageal Neoplasms
5
Carcinoma, Renal Cell
5
Adenocarcinoma Of Esophagus
5
Adenocarcinoma
5
Prostatic Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Neoplasms by Site
4
Mesothelioma
4
Interventions
Radiosurgery
51
Magnetic Resonance Spectroscopy
34
Temozolomide
29
Bevacizumab
24
pembrolizumab
23
Radiotherapy
20
Nivolumab
20
Specimen Handling
14
Ipilimumab
13
Cyclophosphamide
13
Mental Status and Dementia Tests
12
Carboplatin
12
abemaciclib
10
Radiation
10
trastuzumab deruxtecan
8
Proton Therapy
7
Pemetrexed
7
Memantine
7
Blood Specimen Collection
7
fluciclovine F-18
6
binimetinib
6
Paclitaxel
6
Lomustine
6
Etoposide
6
Cisplatin
6
Capecitabine
6
encorafenib
5
Trastuzumab
5
Surveys and Questionnaires
5
Surgical Procedures, Operative
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
durvalumab
×
1 year
×
Clear all
NCT04711824
2025-12-23
SOLARA
Hoosier Cancer Research Network
Phase 1/2
Recruiting
41 enrolled
NCT04538742
2025-12-08
DB-07
AstraZeneca
Phase 1/2
Active not recruiting
245 enrolled